Evolus Inc (EOLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Evolus Inc (EOLS) has a cash flow conversion efficiency ratio of 0.346x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.95 Million) by net assets ($-28.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Evolus Inc (EOLS) net asset quality to measure how much of total assets are equity-financed.
Evolus Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Evolus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Evolus Inc's earnings quality to evaluate the quality of earnings relative to operating cash generation.
Evolus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Evolus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Locaweb Serviços de Internet S.A.
SA:LWSA3
|
0.045x |
|
Nanjing Zhongbei Group Co Ltd
SHE:000421
|
0.037x |
|
Shui On Land Limited
F:OL5
|
0.011x |
|
Yantai Ishikawa Sealing Technology Co.Ltd.
SHE:301020
|
0.002x |
|
AdvanSix Inc
NYSE:ASIX
|
0.032x |
|
Shoppers Stop Limited
NSE:SHOPERSTOP
|
1.280x |
|
Lavvi Empreendimentos Imobiliários S.A
SA:LAVV3
|
-0.003x |
|
Nanjing Inform Storage Equip
SHG:603066
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Evolus Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Evolus Inc from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Evolus Inc (EOLS) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-23.11 Million | $-42.27 Million | 1.829x | +156.12% |
| 2024-12-31 | $5.52 Million | $-18.00 Million | -3.260x | -298.29% |
| 2023-12-31 | $-20.69 Million | $-34.01 Million | 1.644x | +135.81% |
| 2022-12-31 | $18.50 Million | $-84.91 Million | -4.590x | -1025.61% |
| 2021-12-31 | $81.88 Million | $-33.39 Million | -0.408x | -151.41% |
| 2020-12-31 | $-72.96 Million | $-57.87 Million | 0.793x | +167.49% |
| 2019-12-31 | $79.46 Million | $-93.38 Million | -1.175x | -286.39% |
| 2018-12-31 | $84.38 Million | $-25.67 Million | -0.304x | -276.28% |
| 2017-12-31 | $-75.54 Million | $-13.04 Million | 0.173x | -90.76% |
| 2016-12-31 | $-7.11 Million | $-13.27 Million | 1.867x | +161.59% |
| 2015-12-31 | $12.00 Million | $-36.38 Million | -3.031x | -- |
About Evolus Inc
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels,… Read more